The best performing companies in the healthcare sector this year have all benefited from the weight loss drug boom. Pfizer also hopes to make a comeback with an oral weight loss drug, but the latest developments have raised concerns on Wall Street. On Friday local time, Pfizer announced plans to abandon the development of its experimental weight loss drug danuglipron (taken orally twice a day). As of the time of publication, its stock price has fallen by over 6%, with a decline of nearly 40% for the year.